Sergey Yurasov

Dr. Sergey Yurasov serves as Chief Medical Officer of Black Diamond Therapeutics. He brings over 25 years precision oncology drug development and regulatory expertise to Black Diamond.

Prior to joining the Company, Dr. Yurasov was Chief Medical Officer at Nuvation Bio, where he was instrumental in the Company’s successful public offering, which closed in February 2021, and in addition, spearheaded the Company’s clinical development strategy in multiple oncology indications for a number of small molecule programs. Previously, Dr. Yurasov was the Chief Medical Officer and Senior Vice President of Clinical Development at Immune Design Corp, which was acquired by Merck in March 2019. He also served as Senior Vice President of Clinical Development at Clovis Oncology, where he oversaw clinical development and led clinical teams through regulatory filings for multiple oncology programs. Earlier in Dr. Yurasov’s career, he held positions at ImClone Systems, a subsidiary of Lilly Oncology, and Roche, serving as a medical lead and clinical director.

Dr. Yurasov earned an M.D. from the Russian State Medical University and a Ph.D. from the Research Institute for Pediatric Hematology.